leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12345678910111213...235236»
  • ||||||||||  5-fluorouracil / Generic mfg.
    Clinical, Review, Journal, Metastases:  Chemotherapy and radiotherapy for advanced pancreatic cancer. (Pubmed Central) -  Dec 5, 2024   
    Selection of the most appropriate chemotherapy for individuals still remains unpersonalised, with clinicopathological stratification remaining elusive. Biomarker development is essential to assist in rationalising treatment selection for patients.
  • ||||||||||  AB598 / Arcus Biosci
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov) -  Dec 5, 2024   
    P1,  N=87, Recruiting, 
    Further research is needed to better define patient selection criteria and assess long-term outcomes for these patients. Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Aug 2025 --> Mar 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS
    Review, Journal:  Gastric cancer-Epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: An updated review. (Pubmed Central) -  Dec 2, 2024   
    Additionally, immune checkpoint inhibitors like pembrolizumab and nivolumab offer promising results...This review also highlights the critical need for better screening methods that could facilitate early detection and treatment, potentially improving the prognosis. By integrating epidemiological insights with new therapeutic strategies, this article aims to thoroughly understand of gastric cancer's dynamics and outline a framework for future research and clinical management, advocating for a multidisciplinary approach to tackle this formidable disease.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Journal:  Cetuximab-Induced Pneumonitis: An Overlooked Complication. (Pubmed Central) -  Dec 2, 2024   
    Reports of interstitial pneumonitis with EGFR inhibitors like gefitinib and erlotinib are present in the literature, but pulmonary toxicity with cetuximab has rarely been reported...The patient was started on a chemotherapy regimen of 5-fluorouracil, leucovorin calcium, and irinotecan, and later began immunotherapy with cetuximab...The patient was given high-dose corticosteroid therapy; however, he continued to deteriorate clinically and expired after two weeks of hospital admission. This case emphasizes the need for physician alertness in diagnosing drug-induced lung injury and suggests that other alternative disorders should not be ignored.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease. (Pubmed Central) -  Dec 2, 2024   
    We examined the biochemical and cellular effects of a propargyl linked, non-classical antifolate UCP1162 that shows exceptional potency and resilience in the background of methotrexate resistance...Leucovorin suppressed the cellular effects of UCP1162, consistent with UCP1162 working as an antifolate...Long-term exposure to UCP1162 resulted in static culture expressing stem cell genes (CD34, ABCG2, ABCB1), adaptive genes (TCN2, CDKN1A), and genes that might serve as therapeutic targets (TPBG/5T4, TNFRSF10A, ACE). These findings suggest that UCP1162 is a unique tool for studying cellular responses to long-term antifolate treatment and holds promise as a lead compound capable of overcoming some forms of antifolate resistance.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Retrospective data, Journal, Metastases:  Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study. (Pubmed Central) -  Dec 1, 2024   
    We aimed to compare FOLFIRI and bevacizumab with FOLFIRI and aflibercept in terms of overall survival (OS), progression-free survival (PFS) and safety in patients with RAS-mutant metastatic colon cancer who progressed after first-line FOLFOX or XELOX and bevacizumab treatment...As a result of our study, in patients with metastatic RAS-mutant colon cancer who progressed after first-line oxaliplatin-based doublet chemotherapy and bevacizumab, better OS and PFS results were obtained in patients receiving bevacizumab with FOLFIRI compared to patients receiving aflibercept with FOLFIRI. In addition, the side effect profile was more tolerable in the bevacizumab arm.
  • ||||||||||  GSK5764227 / GSK
    Enrollment open, Trial primary completion date:  A Study of GSK5764227 in Participants With. Advanced Solid Tumors (clinicaltrials.gov) -  Nov 29, 2024   
    P1,  N=240, Recruiting, 
    The FOLFIRINOX and VE-822 combination is a promising strategy to improve FOLFIRINOX efficacy and overcome drug resistance in PDAC. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2026 --> Jul 2026
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Biomarker, Journal:  Radial Data Visualization-Based Step-by-Step Eliminative Algorithm to Predict Colorectal Cancer Patients' Response to FOLFOX Therapy. (Pubmed Central) -  Nov 27, 2024   
    Additionally, the procedure developed based on expression levels of TMEM182, MCM9, LRRFIP1, LAMP1, FAM161A, KLHL36, ETV5, RNF168, SRSF11, NCKAP5, CRTAP, VAMP2, ZBTB49 and RIMBP2 proved to be capable in predicting FOLFOX therapy response. In conclusion, our approach can give a unique insight into clinical decision-making regarding therapy scheme administration, potentially increasing patients' survival and, consequently, medical futility due to incorrect therapy application.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Retrospective data, Review, Journal, Combination therapy:  Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Nov 27, 2024   
    Background/Objectives: Camptothecin (CPT) and its derivatives, irinotecan and topotecan, are integral components of cancer chemotherapy, often used in combination therapies...In COLRC, irinotecan and 5-fluorouracil/leucovorin plus bevacizumab demonstrated superior efficacy with a RR of 44% (95% CI: 34-58, p < 0.001) and minimal haematological toxicity...Among the various combinations discussed in this analysis, irinotecan plus cisplatin demonstrated the highest objective RR in 12 trials focused on NSCLC. This study provides valuable insights into potential treatment strategies for various types of cancer, emphasising the importance of personalised and tailored approaches to maximise efficacy and minimise adverse effects.
  • ||||||||||  Review, Journal, BRCA Biomarker, IO biomarker:  Novel Therapies for Pancreatic Cancer. (Pubmed Central) -  Nov 26, 2024   
    Alternative approaches to incorporate immunotherapy have shown more promise such as use of immune checkpoint inhibitors for selected patients in the maintenance setting and potential vaccine therapies in the postsurgery adjuvant setting. It is vital to perform molecular profiling in all patients with PDAC to identify potential treatment targets, and to enroll patients in clinical trials whenever possible.
  • ||||||||||  Observational data, Journal, Metastases:  Pre-operative total neoadjuvant therapy in locally advanced rectal cancer patients: Initial results of Vietnamese patients. (Pubmed Central) -  Nov 25, 2024   
    In a real-world clinical setting, FOLFOXIRI plus bevacizumab demonstrated efficacy and safety comparable to previous clinical trials. A prospective study in 75 patients with stage II and III rectal cancer at 108 Military Central Hospital and Nghe An Oncology Hospital from April 2022 to January 2024 who received total neoadjuvant therapy (preoperative chemoradiation of 50.4 Gy concurrent with Capecitabine 825 mg/m
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Head-to-Head, Surgery:  CAIRO6: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (clinicaltrials.gov) -  Nov 25, 2024   
    P2/3,  N=358, Active, not recruiting, 
    A prospective study in 75 patients with stage II and III rectal cancer at 108 Military Central Hospital and Nghe An Oncology Hospital from April 2022 to January 2024 who received total neoadjuvant therapy (preoperative chemoradiation of 50.4 Gy concurrent with Capecitabine 825 mg/m Trial primary completion date: Dec 2025 --> Oct 2024
  • ||||||||||  Opdivo (nivolumab) / BMS
    Journal:  SMARCA4 Deficient Gastric Carcinoma With Squamous Differentiation in a Young Patient With Aggressive Clinical Course. (Pubmed Central) -  Nov 18, 2024   
    Despite multidisciplinary management, including FOLFOX chemotherapy, immunotherapy (nivolumab), and surgical resection, the patient succumbed to his disease within 2 years of diagnosis. This case report highlights the aggressive nature of SMARCA4-deficient carcinomas, which are often resistant to conventional chemotherapy, and underscores the importance of early diagnosis and exploring alternative therapeutic approaches for such malignancies.
  • ||||||||||  Vyloy (zolbetuximab-clzb) / Astellas
    Enrollment closed, Monotherapy:  ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) -  Nov 17, 2024   
    P2,  N=143, Active, not recruiting, 
    Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025 Recruiting --> Active, not recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Journal, Metastases:  Effect of FOLFOX regimen combined with cetuximab treatment on the efficacy and tumor markers of advanced colon cancer patients. (Pubmed Central) -  Nov 17, 2024   
    Surgeons should consider possible surgical resection and DLM management when selecting the primary treatment. Despite inducing rash, which is controllable, the combined therapy of FOLFOX and cetuximab significantly improves short-term efficacy, reduces the levels of CEA, CA19-9, VEGF-A and VEGFR2, and extends the PFS and OS of patients, which can be served as an effective treatment strategy for advanced colon cancer.
  • ||||||||||  Journal:  Results of the prospective EORTC Children Leukemia Group study 58081 in precursor B- and T-cell acute lymphoblastic leukemia. (Pubmed Central) -  Nov 16, 2024   
    Leucovorin rescue was delayed to 42?h instead of 36?h after initiation of high-dose methotrexate, and a postconsolidation MRD time point was added to stratify patients...The HR was 2.15 (99% CI: 0.67-6.85) for very low-risk but 0.34 (99% CI: 0.13-0.89) for AR2. The particularly favorable results observed in the T-ALLs and AR2 subgroups suggest the benefit of using DXM in specific patient groups and highlight the importance of risk stratification.